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Autophagy is a cooperative process between autophagosomes and lysosomes that degrades cellular
organelles. Although autophagy regulates the turnover of cellular components, its role in melano-
genesis is not clearly established. Previously, we reported that ARP101 induces autophagy in various
cancer cells. Here, we show that ARP101 inhibits melanogenesis by regulation of autophagy. ARP101
inhibited a-MSH-stimulated melanin synthesis and suppressed the expression of tyrosinase and
TRP1 in immortalized mouse melanocytes. ARP101 also induced autophagy in melanocytes. Knock-
down of ATG5 reduced both anti-melanogenic activity and autophagy mediated by ARP101 in a-MSH
treated melanocytes. Electron microscopy analysis further revealed that autophagosomes engulf
melanin or melanosome in a-MSH and ARP101-treated cells. Collectively, our results suggest that
ARP101 inhibits a-MSH-stimulated melanogenesis through the activation of autophagy in
melanocytes.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Epidermal melanocytes synthesize melanin within melano-
somes, a lysosome-related organelle. Melanin is a biological
pigmentation factor that imparts color to the skin or hair [1].
Normal synthesis and production of melanin protects the skin from
UV radiation [2]. However, abnormal production of melanin is
linked to various skin diseases including acquired hyperpigmenta-
tion, melasma and age spots. Melanogenesis involves multiple
processes, including melanin synthesis, transport, and melano-
some release. Melanogenesis is regulated by several key regulator
proteins. In the process of UV radiation, a-MSH (alpha-melanocyte
stimulating hormone) is produced and it stimulates melanocortin
1 receptor that increases the expression of microphthalmia-
associated transcription factor (MITF) through cAMP activation.
MITF is the core controller in the expression of melanogenesis-
related proteins such as tyrosinase and tyrosinase-related protein
(TRP)-1/2, which are responsible for the rate-limiting step in mela-nogenesis [3,4]. Thus, many tyrosinase inhibitors such as arbutin
and kojic acid have been used to regulate hyperpigmentation.
Recently it has been suggested autophagy is involved in mela-
nogenesis [5,6]. Autophagy is a cellular degradation process for
damaged organelles, cellular aggregates, and long-lived proteins
via the lysosome-dependent machinery [7]. Autophagy, which
basically functions as a cell-protective response, is induced upon
cellular stresses such as starvation, organelle damage, pathogen
invasion, and oxidative stress. Nonetheless, excessive activation
of autophagy can contribute to cell death event under certain con-
ditions [8–10]. Therefore, dysfunction of autophagy has been
implicated in various diseases such as neurodegenerative
disorders, cancer, autoimmune diseases, and diabetes [8–10].
Autophagy has been considered a non-selective bulk-degradation
pathway. However, recent studies elucidated selective autophagy
that eliminates speciﬁc organelles, such as ER-phagy and
mitophagy for ER- and mitochondria-speciﬁc degradation respec-
tively [11]. The degradation of melanosome by autophagy is largely
unknown. A recent functional genome screening study revealed
that some autophagy regulatory genes such as WIPI1 (WD repeat
domain, phosphoinositide-interacting protein 1) and ATG6 play a
role in pigment accumulation [5]. Moreover, Murase et al. showed
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of melanin degradation in keratinocytes [12].
Although autophagy participates in melanogenesis, its role in
melanogenesis in melanocytes has not been well deﬁned. We pre-
viously showed that ARP101 (C20H26N2O5S), known as MMP-2
inhibitor strongly induces autophagy and autophagy-associated
cell death in various cancer cells [13,14]. In this study, we observed
that autophagy induced by ARP101 regulates melanogenesis.
2. Materials and methods
2.1. Cell culture
TheMelan-a cells, immortalizedmousemelanocyteswere kindly
provided by Dr. Dorothy C. Bennett (St. George’s Hospital Medical
School, London, UK) The cells were cultured at 37 C in a 5% CO2
humidiﬁed incubator and grown in RPMI 1640 medium (Hyclone,
Thermo Scientiﬁc, Logan, UT) supplemented with 10% fetal bovine
serum (Invitrogen, Calsbad, CA), 1% penicillin/streptomycin, and
200 nM phorbol-12-myristate-13-acetate (Sigma, St. Louis, MO).
2.2. Reagents
ARP101, Actinonin (broad MMP inhibitor), and Z-PLG-NHOH
(MMP-2 and -9 selective inhibitor) were purchased from TOCRIS
(St. Louis, MO) and Sigma–Aldrich (St. Louise, MO). a-MSH,
Arbutin, Baﬁlomycin A1, and Hydroxychloroquine were purchased
from Sigma–Aldrich. The expression plasmid pEGFP-LC3 was
kindly provided by Dr. Noboru Mizushima (Tokyo Medical and
Dental University, Japan) [15]. The validated siRNA for mouse
ATG5 siRNA (50-ACCGGAAACUCAUGGAAUA-30) [16], mouse ATG7
siRNA (50-GAGCGGCGGCUGGUAAGAACA-30), and scrambled con-
trol siRNA (50-CCUACGCCACCAAUUUCGU-30) were synthesized
from Bioneer (Daejeon, Korea)
2.3. Melanin assay
The determination of melanin contents was performed using a
slight modiﬁcation of a previously described method [17]. Melan-
a cells were transfected with either scrambled control siRNA or
ATG5 siRNA. After 48 h, the cells were treated with a-MSH
(1 lM) for 24 h. Then the cells were exposed to ARP101 (10 lM)
for additional 24 h. To measure the melanin contents, the cells
were harvested by trypsinization and dissolved with soluble buffer
(1 M NaOH containing 10% DMSO) at 100 C for 30 min, and then,
relative melanin content was determined by measuring at 415 nm
using an ELISA plate reader (Victor X3, Perkin elmer). In addition,
Melan-a cells were treated with ARP101 (10 lM) and arbutin
(500 lM) in the presence of a-MSH (1 lM). After 48 h, the cells
were harvested by trypsinization and measured melanin contents
using an above described methods.
2.4. Autophagy analysis
Melan-a cells were transfected with pEGFP-LC3 using Lipofect-
amine 2000 according to manufacturer’s protocol (Invitrogen,
Carlsbad, CA). Then the cells were treated with ARP101 (10 lM)
and autophagy was determined by counting of the number of cells
with GFP-LC3 punctate structures under a ﬂuorescence microscopy
(IX71, Olympus, Japan).
2.5. Cell viability assay
Melan-a cells were seeded in 96-well plates. After treatment of
ARP101, the cells were incubated for 24 h. Cell viability was deter-mined through the reduction of WST-8 to water soluble formazan
using a Cell Counting Kit-8 (CCK-8) (Dojindo Laboratories, kuma-
moto, Japan). CCK-8 was added to each well at 1/10 volume of
media. The cells were incubated at 37 C for 30 min. The absor-
bance change was measured at 450 nm using a micro plate reader.
2.6. Western blot analysis
The protein extract was isolated from cells using a 2 Laemmli
sample buffer (Bio-Rad, Hercules, CA). After separation in 10–15%
SDS–PAGE, protein was transferred onto polyvinylidene ﬂuoride
membrane (Bio-Rad, Hercules, CA). The membrane was blocked
with 5% skim milk in TBST for 1hr and then incubated with speciﬁc
primary antibodies overnight at 4 C. Anti-ATG5 (ab54033) and
anti-ATG7 (ab53255) antibodies were purchased from Abcam
(Cambridge, UK); anti-LC3 (NB100-2220) antibody was purchased
from NOVUS Biologicals (Littleton, CO); anti-MITF (sc-5625) anti-
body; anti-p62 (sc-28359) antibodies were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA); anti-Actin (MAB1501) anti-
body was purchased from Millipore (Temecula, CA); anti-
Tyrosinase and anti-TRP1 antibodies were kindly donated by V.J.
Hearing (NIH, Bethesda, MD). For protein detection, the mem-
branes were incubated with HRP-conjugated secondary antibodies
and signals were detected with Super-signal West Dura HRP detec-
tion kit (Pierce, Rockford, IL).
2.7. Statistical analysis
The results were expressed as the means ± S.E.M. The probabil-
ity of statistical differences between experimental groups was
determined by the Student’s t-test. A P-value < 0.05 was consid-
ered statistically signiﬁcant.
3. Results
3.1. ARP101 inhibits a-MSH-stimulated melanogenesis in melanocytes
In this study, we used Melan-a melanocytes as the cell model to
assess the effect of ARP101 on melanogenesis (Fig. 1A). To examine
the cytotoxicity of ARP101, we ﬁrst assessed cell viability. As
shown in Fig. 1B, ARP101 showed no signiﬁcant cytotoxic effect
on the Melan-a cells at a concentration of 15 lM, but slightly de-
creased cell viability at a higher concentration (20 lM). Therefore,
we used 10 lM ARP101 for further experiments. To examine the
effect of ARP101 on melanin synthesis, Melan-a cells stimulated
with of a-MSH were further treated with either ARP101 or arbutin,
a well-known tyrosinase inhibitor. The a-MSH treatment efﬁ-
ciently induced melanin synthesis. And excessive melanin produc-
tion was almost completely inhibited by ARP101 co-treatment
(Fig. 1C and D). We further evaluated the protein expression level
of key regulators of melanogenesis after ARP101 treatment. The
expression levels of tyrosinase, TRP1 as well as MITF were remark-
ably increased by a-MSH treatment. In these cells, ARP101 treat-
ment reduced the expression of tyrosinase, TRP1, and MITF,
while arbutin did not affect the expression of those proteins
(Fig. 1E). These results suggest that ARP101 inhibits a-MSH-stimu-
lated melanin synthesis by down-regulation of melanogenesis reg-
ulators in melanocytes.
3.2. ARP101 induces autophagy in melanocytes
Previously, we reported that ARP101 strongly induces autoph-
agy in various cancer cell lines [14]. However, autophagy inducing
capacity of ARP101 in the melanocytes has not been elucidated.
Thus, we next examined the effect of ARP101 on autophagy in
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Fig. 1. ARP101 inhibits a-MSH-stimulated melanogenesis in Melan-a cells. (A and B) Chemical structure of ARP101. (A) Melan-a cells were incubated with various
concentrations of ARP101 for 24 h then, the cell viability was determined with CCK-8 assay. (C–E) Melan-a cells pre-treated with a-MSH were further incubated with either
ARP101 (ARP, 10 lM) or Arbutin (500 lM). After harvesting, the cell pellets were shown. (C) And the melanin contents were measured as described in Section 2. (D) The
expression level of tyrosinase (TYR), tyrosinase related protein-1 (TRP1), and MITF was analyzed by Western blotting. (E) Data were obtained from least three independent
experiments and values are presented as the means ± S.E.M. (⁄P < 0.02).
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Fig. 2. ARP101 induces autophagy in Melan-a cells. (A) Melan-a cells transiently
transfected with GPF-LC3 were treated with or without ARP101 (10 lM) for 24 h.
Then, the cells were ﬁxed to take a ﬂuorescence picture. (B and C) Melan-a cells
expressed GFP-LC3 were exposed to increasing concentration of ARP101 (5, 10 lM).
Cells with autophagic puncta were counted under a ﬂuorescence microscope (B).
And the cells exposed to ARP101 for 24 h were harvested and subjected into
Western blot analysis with LC3 and p62 antibodies (C). (D) Melan-a cells were
treated with ARP101 (ARP, 10 lM) in the presence or absence of an autophagy
inhibitor, Baﬁlomycin A1 (Baﬁlo). The expression level of LC3 protein was detected
by Western blotting. Data were obtained from least three independent experiments
and values are presented as the means ± S.E.M. (⁄P < 0.02).
E.S. Kim et al. / FEBS Letters 587 (2013) 3955–3960 3957melanocytes. Both the formation of punctate structures with GFP-
fused LC3 protein and an increase in the production of LC3II pro-
tein have been generally used as indicator of autophagy activation
[7]. Thus, we also determined ARP101-induced autophagy by using
LC3 proteins. ARP101 treatment resulted in increased conversion
of LC3 to LC3 II and degradation of p62 protein as well as induced
the formation of autophagic punctate structures with GFP-LC3 pro-
teins (Fig 2A-C). To conﬁrm the autophagy activation by ARP101,
we measured autophagic ﬂux with a lysosome inhibitor, Baﬁlomy-
cin A1. Increased accumulation of LC3 protein after combination
treatment of ARP101 and Baﬁlomycin A1 indicated active autopha-
gic ﬂux by ARP101 (Fig 2D). ARP101 is known as a selective MMP-2
inhibitor. Thus, we further investigated whether MMP-2 activity
affects to melanogenesis or not. Unlike ARP101, either Actinonin,
a broad MMPs inhibitor or Z-PLG-NHOH, MMP-2 and -9 speciﬁc
inhibitor did not affect to the reduction of a-MSH–mediated
melanognesis as well as induction of autophagy in melanocytes
(Supplementary Fig. 1). Taken together, these results suggest that
ARP101 also highly induces autophagy in melanocytes.
3.3. Inhibition of autophagy attenuates anti-melanogenic activity of
ARP101
Since ARP101 induces autophagy in melanocytes, we next
investigated the effect of inhibition of autophagy in ARP101-
treated cells. Among several autophagy-related genes (ATGs), the
ATG5 gene is essential for the initiation of autophagosome forma-
tion. Thus, we examined the effect of ATG5 down-regulation in
ARP101-treated melanocytes. According to the previous reports,
both formation of autophagic punctates and conversion of LC3I
to LC3 II were remarkably suppressed in ATG5 knock-down cells
compared to the control cells (Fig. 3A and B). Recent evidences
3958 E.S. Kim et al. / FEBS Letters 587 (2013) 3955–3960suggest that autophagy plays a role in melanosome destruction
and biogenesis [6,18]. Thus, we further examined the effect of
ATG5 down-regulation on melanin synthesis after ARP101 treat-
ment in a-MSH-treated cells. Interestingly, depletion of ATG5 itself
slightly increased melanin production. Furthermore, inhibition of
ATG5 notably reduced the anti-melanogenic effect of ARP101 in
a-MSH treated melanocytes (Fig. 3C). Moreover, treatment of
chemical inhibitor of autophagy such as Baﬁlomycin A1 and
hydroxychloroquine also increased melanin contents in Melan-a
cells (Supplementary Fig. 2). The effect of suppression of autoph-
agy on ARP101-mediated anti-melanogenesis was further deter-
mined by Western blotting analysis. Consistent with melanin
content results, knock-down of ATG5 led to the recovery of the re-
duced tyrosinase protein levels by ARP101 in a-MSH-stimulated
cells (Fig. 3D). These results suggest that the anti-melanogenic ef-
fect of ARP101 is associated with autophagy activation.
3.4. Autophagosome induced by ARP101 contains melanin in
melanocytes
The most direct evidence of autophagy is the observation of
autophagosomes by electron microscopy (EM). To further verify
that melanogenesis is regulated by autophagy, we directly exam-
ined cellular autophagosomes and melanosomes with EM. Auto-
phagosomes, specialized structures surrounded by two distinct
lipid bilayers, can be detected in cells undergoing autophagy by
using EM. Treatment with a-MSH induced melanin accumulation
in cells (Fig. 4A and B). Most importantly, EM analysis revealed thatA
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Fig. 3. Inhibition of autophagy suppressed ARP101-mediated anti-melanogenic acitivity
autophagy. Melan-a cells transfected with scrambled control siRNA (Sc) or ATG5 siRN
ARP101 (10 lM). Autophagy was determined by counting of the punctate GFP-LC3 dots u
were also examined by Western blot analysis (B). (C and D) Melan-a cells were transfecte
with a-MSH (1 lM) for 24 h were exposed to 10 lM ARP101 for additional 24 h. After 96
(C). The tyrosinase expression was assessed with Western blotting (D). Data represent ± s
n > 3, ⁄P < 0.01).autophagosomes engulfed melanin or melanosomes following
combined treatment with a-MSH and ARP101 (Fig. 4C). Taken to-
gether, our data suggest that autophagy is induced by ARP101 that
regulates melanogenesis.
4. Discussion
Melanocytes produce melanin through melanogenesis. Various
stimuli such as UV irradiation and hormones are able to modulate
the melanogenesis in melanocytes. However, the mechanism
underlying its regulation is not fully understood. More than 100
genes are involved in the complex process of melanogenesis,
encoding structural and functional regulatory proteins [19].
Among them, tyrosinase is responsible for the rate liming step in
melanin biosynthesis. Thus, its activity is correlated with melanin
content [20]. Hence, many anti-melanogenic agents including
arbutin and resveratrol negatively regulate tyrosinase activity. In
this study, we found that ARP101 has anti-melanogenic activity
in melanocytes. Treatment with ARP101 notably suppressed
a-MSH-induced accumulation of melanin in melanocytes.
Furthermore, ARP101 suppressed a-MSH-induced up-regulation
of tyrosinase and TRP1 (Fig. 1). Previous studies showed several
antioxidants negatively regulate melanogenesis, and can inhibit
MMPs [21–23]. However, MMP activity does not affect to
ARP101-mediated anti-melanogenesis. MMP inhibition by
Actinonin or Z-PLG-NHOH did not induce the reduction of
a-MSH–mediated melanognesis as well as induction of autophagy
in Melan-a cells (Supplementary Fig. 1). MITF, the earliestLC3 
LC3 
Actin
ATG5-ATG12
B
Sc
Sc/
ARP
siATG5
/ARP
TYR 
Actin
ATG5
LC3 ǀ
LC3 II
-
-
-
+
+
-
-
-
+
+
-
+
-
+
+
+
+
+
ATG5
P101
-MSH
-
+
-
+
-
-
in Melan-a cells. (A and B) Depletion of ATG5 by siRNA suppresses ARP101-induced
A (siATG5) were expressed with GFP-LC3, and the cells were further treated with
nder a ﬂorescence microscope (A). The protein expression levels of the LC3 and ATG5
d with control scrambled siRNA and ATG5 siRNA. After 2 days, the cells pre-treated
h from transfection, the cells were harvested and lysed to measure melanin contents
tandard error of the mean (S.E.M.) from more than three independent experiments,
A B
Con α-MSH
C
α-MSH + ARP101
Fig. 4. Autophagosomes mediated by ARP101 contains melanin in Melan-a cells. (A) Melan-a cells were observed by electron microscopy as described in Section 2. (B) Melan-
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cule in melanocyte development and melanogenesis [24]. MITF le-
vel is regulated by transcriptional control of the MITF gene and by
post-translational modiﬁcation of the MIFT protein. For example,
a-MSH up-regulates MITF via transactivation of the MITF gene by
cAMP signaling cascade. And phosphorylation or sumoylation of
the MITF protein regulates protein destabilization [25]. Because
MITF mainly controls the expression of key regulators in melano-
genesis such as tyrosinase and TRP1/2, we investigated the effect
of ARP101 on MITF expression. As shown in Fig. 1E, ARP101 also
slightly suppressed a-MSH-mediated up-regulation of MITF. Thus,
further studies are needed to determine the function of ARP101 on
the regulation of melanogenesis especially focusing on the down-
stream of MITF.
ARP101 showed differential cytotoxic effect on normal and can-
cer cells. ARP101 efﬁciently induced autophagy-associated cell
death in cancer cells at a low concentration (<5 lM) [14]. More-
over, we conﬁrmed the cytotoxic effect of ARP101 on B16F1 mela-
noma cells (data not shown). However, ARP101 did not show
signiﬁcant cytotoxicity at 15 lM in melanocytes such as Melan-a
cells and human normal melanocytes but ARP101 slightly induced
cell death at 20 lM concentration in Melan-a cells. Cancer cells and
normal cells have different physical features. A lot of genes differ-
ently expressed in normal and cancer cells [26]. Some of the differ-
ences are well known, whereas others have only been recently
discovered and are less well understood [27]. The expression of
MMP-2 is increased in cancer cells and it is associated with tumor
progression in melanoma [28,29]. MMP-2 and MMP-9 were con-
sidered to be target for anti-cancer drug development [30].
ARP101 is strong MMP-2 inhibitor. And the different expressionof MMP-2 may affect different cytotoxic effect to ARP101 on nor-
mal and cancer cells. Thus, it will be important to investigate the
mechanisms underlying the differential response to ARP101 be-
tween melanocytes and melanoma cells.
Autophagy is responsible for degrading the damaged or un-
wanted cellular components and organelles [8,9]. We hypothesized
that autophagy is functionally associated with the regulation of
melanogenesis. Because ARP101 is as a strong autophagy inducer
in various cell types, we examined the effect of ARP101 on melano-
genesis in terms of autophagy activation in this study. Consis-
tently, our results show that the conversion of the LC3 protein,
the degradation of p62 protein, and the formation of autophagic
punctate were highly induced by ARP101 treatment in
melanocytes (Fig. 2). Interestingly, recent studies suggested that
autophagy is involved in the regulation of melanogenesis. Down-
regulation of WIPI1, a human homologue of the yeast ATG18 pro-
tein suppressed the transcriptional activation of MITF and its target
genes [5,6,31].
Murase et al. recently showed that autophagy promotes mela-
nosome’s degradation in normal human epidermal keratinocytes
(NHEKs) but not in normal human epidermal melanocytes
(NHEMs). Down-regulation of ATG7 by RNA interference enhanced
both PMEL17 protein expression and melanin contents in NHEKs.
However, inhibition of ATG7 decreased melanin contents in
NHEMs. Additionally, treatment with an autophagy activator such
as rapamycin resulted in reduced melanin contents in skin-derived
NHEKs [12]. Hah et al. showed that rapamycin promotes melano-
genesis by the up-regulation of tyrosinase protein in melanoma
cells [32]. Thus, we further addressed the effect of autophagy on
melanogenesis in melanocytes by using ARP101. In contrast to
3960 E.S. Kim et al. / FEBS Letters 587 (2013) 3955–3960the previous reports, we found that genetic or chemical inhibition
of autophagy increased melanin production in both Melan-a mela-
nocytes and B16F1 melanoma cells (Supplementary Fig. 2). In
addition, inhibition of autophagy by ATG5 siRNA suppressed
ARP101-mediated anti-melanogenic effect in a-MSH treated
Melan-a cells (Fig. 3C and D). Our results strongly suggest that sup-
pression of autophagy induced by ARP101 resulted in a signiﬁcant
recovery from both reduced melanin production and tyrosinase
protein level in a-MSH treated melanocytes. Moreover, we directly
observed engulfment of melanin into autophagosomes by EM anal-
ysis (Fig. 4). Similar in NHEKs, autophagy machinery may degrade
over-produced melanosomes in melanocytes. Nonetheless, the
different results from NHEMs and Melan-a cells should be further
investigated.
In conclusion, our ﬁndings show that treatment with ARP101
inhibits hyper-pigmentation induced by a-MSH in melanocytes,
and that the anti-melanogenic activity of ARP101 is associated
with autophagy activation. Although the effects of ARP101 on mel-
anosome transfer to keratinocyte and functions of ARP101 in kerat-
inocytes are yet to be elucidated, our ﬁndings suggest that ARP101
could serve as an effective agent for anti-melanogenesis. Taken to-
gether, autophagy regulators may provide a novel experimental
tool for the control of skin pigmentation.
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